Publications (100) Manuel Mateo Pérez Encinas publications

2024

  1. Evolving patterns and clinical outcome of genetic studies performed at diagnosis in acute myeloid leukemia patients: Real life data from the PETHEMA Registry

    Cancer, Vol. 130, Núm. 20, pp. 3436-3451

  2. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

    Leukemia

  3. Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience

    Annals of Hematology, Vol. 103, Núm. 2, pp. 451-461

  4. Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis

    HemaSphere

  5. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

    Haematologica, Vol. 109, Núm. 1, pp. 115-128

  6. Prognostic value of response to first-line hydroxyurea according to IPSET stratification in essential thrombocythemia

    Leukemia

  7. The prognostic impact of non-driver gene mutations and variant allele frequency in primary myelofibrosis

    American Journal of Hematology

  8. Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification

    British Journal of Haematology, Vol. 204, Núm. 4, pp. 1529-1535

2023

  1. A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

    Frontiers in Oncology, Vol. 13

  2. Application of IPSET-Thrombosis in 1366 Patients Prospectively Followed from the Spanish Registry of Essential Thrombocythemia

    HemaSphere, Vol. 7, Núm. 8, pp. E936

  3. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  4. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

    Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901

  5. Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia(Front. Oncol., (2022), 12, (968340), 10.3389/fonc.2022.968340)

    Frontiers in Oncology

  6. First description of bone marrow failure syndrome in Spain caused by mutations in the ERCC6L2 gene

    British Journal of Haematology

  7. Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes

    HemaSphere, Vol. 7, Núm. 10, pp. E961

  8. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

    HemaSphere, Vol. 7, Núm. 1, pp. E818

  9. Prediction of major bleeding events in 1381 patients with essential thrombocythemia

    International Journal of Hematology, Vol. 118, Núm. 5, pp. 589-595

  10. Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment

    Cancers, Vol. 15, Núm. 13

  11. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

    Cancers, Vol. 14, Núm. 9